Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
Clinical trial NCT07416539 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07416539
- Sponsor
- Rokote Laboratories Finland Oy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-10
- Primary completion
- 2026-11-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.